Plexus Q4 Call: Record Revenue and Raised Outlook Test Bear Thesis

What happened

Plexus reported record fourth-quarter revenue and raised its fiscal 2027 growth outlook, citing stronger end-market demand, program ramps, and market-share gains across aerospace and defense, healthcare, and industrial. The call's commentary implies that the company's long-stressed conversion of its ~$1 billion annualized program wins may finally be materializing. This stands in contrast to the prior DeepValue report's 'Potential Sell' rating, which hinged on low single-digit revenue growth and concerns that EMEA softness and customer disengagements would offset new wins. While management's tone is clearly optimistic, a record top line alone does not confirm that margins and free cash flow have improved commensurately. Investors should note that the stock still trades at roughly 28x trailing EPS with a free cash flow yield of only ~2%, leaving little room for execution missteps.

Implication

The raised fiscal 2027 outlook suggests that management expects growth acceleration, but the prior report's base case called for only 5-7% annual revenue growth; if the new guidance implies high single digits or more, it could justify a higher multiple. However, at ~28x trailing EPS, the market appears to already price in improved fundamentals, offering limited cushion if execution falters. Key monitoring points will be whether revenue growth is broad-based or concentrated, whether non-GAAP operating margin holds near 6%, and whether free cash flow recovers from the guided ~$100 million step-down. For existing holders, the news reduces the urgency to trim, but adding at current levels requires conviction that the growth inflection is durable and that EMEA is no longer a drag. For new investors, waiting for a pullback toward the $170 base-case implied value or for more than one quarter of confirmed acceleration may offer a better entry point.

Thesis delta

The new information modestly weakens the bear case by showing that program wins are beginning to convert into revenue growth and that management is confident enough to raise the fiscal 2027 outlook. However, the core issue remains valuation at ~28x earnings with a mid-single-digit free cash flow yield, so the thesis shifts from 'potential sell' to 'hold with a skeptical bias' pending confirmation of margin and cash flow improvement. A sustained acceleration to high single-digit revenue growth and stable ~6% operating margin would be needed to justify a more constructive stance.